Urinary Tract Infections Market

Urinary Tract Infection Treatment Market: Improving access to essential drugs & rising public awareness fueling revenue growth: Global Industry Analysis and Opportunity Assessment, 2016 – 2026

Ask The Analyst Customization Available Request Methodology

Urinary tract infection (UTI) occurs in the bladder, urethra, ureter, and kidneys due to colonization of microbial pathogens in these parts. UTI infections can be complicated or uncomplicated, based on the severity of infection. Amoxicillin is a penicillin antibiotic used to treat UTIs and is one of the most commonly prescribed antibiotic for uncomplicated UTIs. Urinary tract infection is among the most common bacterial infections affecting millions of persons worldwide. Recurrent urinary tract infection is a major health issue in females across the globe. Patients with urinary catheter or spinal cord injury are most likely to contract complicated UTIs.

Among non-institutionalized geriatric population, UTIs are the second-most common infection and estimated to account for around 25% of all bacterial infections.

Market Value and Forecast

The global Urinary tract infection treatment market was valued at US$ 9.2 Bn in 2015, and is projected to expand at a CAGR of 2.1% over forecast period 2016–2026, owing to increasing incidence of UTIs and recurring UTIs, increasing use of urinary catheters, and other drainage devices.

Drivers and Trends

Incidence of chronic diseases are on the rise across the globe. Population with chronic diseases such as diabetes mellitus, chronic institutional residence, neurologic conditions, and chronic indwelling urinary catheterization are more susceptible to developing complicated urinary tract infections. These factors are expected to increase the number of UTI patients and is expected to boost growth of the UTI treatment market over the forecast period. Introduction of combination products to combat multi-drug resistant bacteria and expending indications for existing drugs are some key factors positively affecting market growth.

Analysis by Region

The global urinary tract infection treatment market has been segmented into seven major regions: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), and Japan and Middle East & Africa (MEA). In terms of value, the APEJ market has been estimated to dominate the global urinary tract infection treatment market in 2016, and is expected to witness highest CAGR of 2.4% over the forecast period. Markets in MEA, North America, and Western Europe are estimated to register higher CAGRs as compared to other regional markets. Revenue from the North America market is expected to expand at a CAGR of 2.0% over the forecast period. In North America, the quinolones segment is expected to register a CAGR of 2.6% to reach value of US$ 695.4 Mn by 2026 end.

urinary tract infections market forecast

Analysis by Drug Type

The global urinary tract infection treatment market is segmented into penicillin & combinations, quinolones, cephalosporin, aminoglycoside antibiotics, sulphonamides, azoles and amphotericin B, tetracycline, nitrofurans, and other segments. Penicillin & combinations segment is further sub-segmented into amoxicillin, amoxicillin & clavulanate potassium, and others. Quinolones segment is further sub-segmented into ciprofloxacin, levofloxacin, nalidixic acid, norfloxacin, and others. Cephalosporin segment is further sub-segmented into ceftriaxone, cefuroxime, cefixime, and cephalexin. Aminoglycoside antibodies segment is further sub-segmented into amikacin and gentamicin. Quinolones segment is estimated to account for maximum revenue share in the global urinary tract treatment market. 

Analysis by Indication

By indication, the global urinary tract infection treatment market is segmented into complicated urinary tract infection, recurring complicated urinary tract infection, uncomplicated urinary tract infection, and neurogenic bladder infection. The neurogenic bladder infections indication segment is expected to expand at a CAGR of 2.6% in terms of revenue over the forecast period. The uncomplicated urinary tract infection segment was estimated in 2015 to dominate the overall urinary tract infection treatment market and expected to expand at a healthy CAGR over the forecast period. 

Analysis by Distribution Channel

By distribution channel, the global urinary tract infection treatment market is segmented into hospital pharmacies, gynecology and urology clinics, drug store, retail pharmacies, and online drug stores. The online drug stores distribution channel segment is expected to expand at a CAGR of 2.8% in terms of revenues over the forecast period. The retail pharmacies is estimated to dominate the overall urinary tract infection market and expected to expand at a healthy CAGR over the forecast period

Competitive Landscape

Some of the key players identified in the global urinary tract infection market report include Johnson and Johnsons Private Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., Bayer AG, GlaxoSmithKline Pharmaceuticals Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Novartis AG, and AstraZeneca plc. The report offers valuable insights into company-specific strategies related to the global urinary tract infection market, market consolidation initiatives, and analyses of the various market players’ specific strengths, weaknesses, opportunities, and threats.

An in-depth assessment of the urinary tract infection treatment market is showcased in the research report published by Future Market Insights (FMI) for a period of ten years from 2016 to 2026. The report states that the urinary tract infection treatment market is projected to register a CAGR of 2.1 percent during the period of forecast. The research study is an effective compilation of necessary information pertaining to the market for greater understanding of the future avenues of the market. The study provides meaningful insights with the help of the information presented in light of the current market scenario of the urinary tract infection treatment market.

Report Description

The study highlights the market influencers in major regions across the globe which are expected to impact the current environment and future circumstances of the urinary tract infection treatment market over the forecast period. This research publication by FMI intends to offer insights into advancements in the urinary tract infection treatment market that are capable of transforming the health-care industry into an improved sector.

Extensive research conducted by experienced analysts with well-scrutinized data resulting in qualitative and quantitative insights are major highlights of the report. The urinary tract infection treatment market report commences with the executive summary defining the urinary tract infection and the medication used for its treatment. This section identifies the indications for urinary tract infection proceeded by an overview of the urinary tract infection treatment market. The overview section of the market includes an assessment of the market restraints, drivers, and opportunities followed by the key market trends that are expected to influence the urinary tract infection treatment market. The last section is devoted to an effective assessment of the players in the urinary tract infection treatment market.

Urinary Tract Infection Treatment Market Introduction

The market research study provided by FMI helps the reader attain a greater understanding of the market with a market introduction at the beginning of the report that comprises of a brief market taxonomy and definition. Furthermore, the study highlights key drugs types providing an overview of its comprehensive understanding. Followed by this, the report gives information of the drugs and defines the resistant timeline and clinical trials of the same. The market introduction section is a brief overview of the entire research study that provides necessary analysis of the market influencers and their impact on the current and future market scenario.

Market Segmentation

The research report segments the urinary tract infection treatment market on the basis of indication, drug type, and distribution channel. The report consists of necessary information pertaining to each segment with well-analyzed insights regarding market size and market share analysis. The study effectively covers year-over-year growth rate projection, basis share analysis and absolute ($) opportunity for the period of forecast. Information pertaining to market attractiveness further highlights the opportunities that the urinary tract infection treatment market holds in the future. Furthermore, the inclusion of figures charts and tables provide a precise understanding of the market to the reader. The regional segregation of the market helps evaluate the global scenario of urinary tract infection treatment with numbers stating the scale of each region pertaining to this market. Major markets assessed in this report include North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, and MEA. It helps the reader evaluate the most lucrative regions and provides an overview of the other regions in the picture.

Competitive Analysis

The final section of the report comprises a competitive landscape that provides a dashboard view for the report audience to give a better understanding of the players. This section highlights the strategic actions and key developments carried out by these market players along with the individual company profiles. The inclusion of SWOT analysis of major market players is a key highlight of the report. Major players in the market include GlaxoSmithKline Pharmaceuticals Ltd., Johnson and Johnsons Private Ltd., Boehringer Ingelheim GmbH, Novartis AG., Cipla Ltd., Bayer AG, Pfizer Inc., F.Hoffmann-La Roche Ltd., and AstraZeneca plc.

Urinary Tract Infections Market Reports - Table of Contents

1.Assumptions and Acronyms Used

2.Research Methodology

3.Executive Summary

4.Urinary Tract Infection Treatment Market Overview

4.1. Introduction

4.1.1.Urinary Tract Infection Treatment Market Taxonomy

4.1.2.Urinary Tract Infection Treatment Market Definition

4.1.3.Urinary Tract Infection Treatment Market Drug Type Overview

4.1.4.Global Antibiotic Drugs Availability and Resistant Timeline

4.1.5.Clinical Trials

4.2. Urinary Tract Infection Treatment Market Dynamics

4.2.1.Drivers

4.2.2.Restraints

4.2.3.Opportunity

4.2.4.Trends

4.3. Survey Analysis

4.4. Epidemiology Overview

4.5. PEST Analysis

5.Global Urinary Tract Infection Treatment Market Analysis, By Drug Type 

5.1. Introduction

5.1.1.Y-o-Y Growth Comparison, By Drug Type 

5.1.2.Market Share & Basis Point (BPS) Analysis, By Drug Type

5.1.3.Market Attractiveness Analysis, By Drug Type 

5.2. Market Forecast, By Drug Type 

5.2.1.Penicillin & Combinations 

5.2.1.1. Absolute $ Opportunity

5.2.1.2. Market Value Forecast

5.2.1.3. Amoxicillin

5.2.1.4. Amoxicillin+ Clavulanate Potassium 

5.2.1.5. Others

5.2.2.Quinolones

5.2.2.1. Absolute $ Opportunity

5.2.2.2. Market Value Forecast

5.2.2.3. Ciprofloxacin

5.2.2.4. Levofloxacin

5.2.2.5. Nalidixic acid

5.2.2.6. Norfloxacin

5.2.2.7. Others

5.2.3.Cephalosporin

5.2.3.1. Absolute $ Opportunity

5.2.3.2. Market Value Forecast

5.2.3.3. Cefuroxime

5.2.3.4. Ceftriaxone

5.2.3.5. Cefixime

5.2.3.6. Cephalexin

5.2.4.Aminoglycoside Antibiotics 

5.2.4.1. Absolute $ Opportunity

5.2.4.2. Market Value Forecast

5.2.4.3. Amikacin

5.2.4.4. Gentamicin 

5.2.5.Sulphonamides

5.2.5.1. Absolute $ Opportunity

5.2.5.2. Market Value Forecast

5.2.5.3. Sulfamethoxazole + Trimethoprim

5.2.6.Azoles and Amphotericin B

5.2.6.1. Absolute $ Opportunity

5.2.6.2. Market Value Forecast

5.2.7.Tetracycline

5.2.7.1. Absolute $ Opportunity

5.2.7.2. Market Value Forecast

5.2.7.3. Doxycycline

5.2.8.Nitrofurans 

5.2.8.1. Absolute $ Opportunity

5.2.8.2. Market Value Forecast

5.2.8.3. Nitrofurantoin 

5.2.9.Others

5.2.9.1. Absolute $ Opportunity

5.2.9.2. Market Value Forecast

6.Global Urinary Tract Infection Treatment Market Analysis, By Distribution Channel 

6.1. Introduction

6.1.1.Y-o-Y Growth Comparison, By Distribution Channel 

6.1.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel 

6.1.3.Market Attractiveness Analysis, By Distribution Channel 

6.2. Market Forecast, By Distribution Channel 

6.2.1.Hospital Pharmacies

6.2.1.1. Absolute $ Opportunity

6.2.1.2. Market Value Forecast

6.2.2.Gynecology and Urology Clinics 

6.2.2.1. Absolute $ Opportunity

6.2.2.2. Market Value Forecast

6.2.3.Drug Store

6.2.3.1. Absolute $ Opportunity

6.2.3.2. Market Value Forecast

6.2.4.Retail Pharmacies

6.2.4.1. Absolute $ Opportunity

6.2.4.2. Market Value Forecast

6.2.5.Online Drug Stores

6.2.5.1. Absolute $ Opportunity

6.2.5.2. Market Value Forecast

7.Global Urinary Tract Infection Treatment Market Analysis, By Indication

7.1. Introduction

7.1.1.Y-o-Y Growth Comparison, By Distribution Channel 

7.1.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel 

7.1.3.Market Attractiveness Analysis, By Distribution Channel 

7.2. Market Forecast, By Distribution Channel 

7.2.1.Complicated UTI

7.2.1.1. Absolute $ Opportunity

7.2.1.2. Market Value Forecast

7.2.2.Recurring Complicated UTI

7.2.2.1. Absolute $ Opportunity

7.2.2.2. Market Value Forecast

7.2.3.Uncomplicated UTI

7.2.3.1. Absolute $ Opportunity

7.2.3.2. Market Value Forecast

7.2.4.Neurogenic Bladder Infections

7.2.4.1. Absolute $ Opportunity

7.2.4.2. Market Value Forecast

7.2.4.3.

8.Global Urinary Tract Infection Treatment Market Analysis, By Region

8.1. Introduction

8.1.1.Y-o-Y Growth Projections, By Region

8.1.2.Market Share & Basis Point (BPS) Analysis, By Region

8.1.3.Regional Attractiveness Analysis

8.2. Market Forecast, By Region

8.2.1.North America Market Value Forecast

8.2.2.Latin America Market Value Forecast

8.2.3.Europe Market Value Forecast

8.2.4.Eastern Europe Market Value Forecast

8.2.5.APEJ Market Value Forecast

8.2.6.Japan Market Value Forecast

8.2.7.MEA Market Value Forecast

9.North America Urinary Tract Infection Treatment Market Analysis

9.1. Market Value Forecast, By Country

9.1.1.Y-o-Y Growth Projections, By Country

9.1.2.Market Share & Basis Point (BPS) Analysis, By Country

9.1.3.Market Attractiveness Analysis, By Country

9.1.4.US 

9.1.5.Canada 

9.2. Market Value Forecast, By Drug Type 

9.2.1.Y-o-Y Growth Projections, By Drug Type

9.2.2.Market Share & Basis Point (BPS) Analysis, By Drug Type

9.2.3.Market Attractiveness Analysis, By Drug Type

9.2.4.Penicillin & Combinations 

9.2.4.1. Amoxicillin

9.2.4.2. Amoxicillin+ Clavulanate Potassium 

9.2.4.3. Others

9.2.5.Quinolones

9.2.5.1. Ciprofloxacin

9.2.5.2. Levofloxacin

9.2.5.3. Nalidixic acid

9.2.5.4. Norfloxacin

9.2.5.5. Others

9.2.6.Cephalosporin

9.2.6.1. Cefuroxime

9.2.6.2. Ceftriaxone

9.2.6.3. Cefixime

9.2.6.4. Cephalexin

9.2.7.Aminoglycoside Antibiotics

9.2.7.1. Amikacin

9.2.7.2. Gentamicin

9.2.8.Sulphonamides

9.2.8.1. Sulfamethoxazole + Trimethoprim

9.2.9.Azoles and Amphotericin B

9.2.10.Tetracycline

9.2.10.1. Doxycycline

9.2.11.Nitrofurans 

9.2.11.1. Nitrofurantoin 

9.2.12.Others

9.3. Market Value Forecast, By Distribution Channel

9.3.1.Y-o-Y Growth Projections, By Distribution Channel

9.3.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel 

9.3.3.Market Attractiveness Analysis, By Distribution Channel

9.3.4.Hospital Pharmacies

9.3.5.Gynecology and Urology Clinics 

9.3.6.Drug Stores

9.3.7.Retail Pharmacies

9.3.8.Online Drug Stores

9.4. Market Value Forecast, By Indication

9.4.1.Y-o-Y Growth Projections, By Indication

9.4.2.Market Share & Basis Point (BPS) Analysis, By Indication

9.4.3.Market Attractiveness Analysis, By Indication

9.4.4.Complicated UTI

9.4.5.Recurring Complicated UTI

9.4.6.Uncomplicated UTI

9.4.7.Neurogenic Bladder Infections

10. Latin America Urinary Tract Infection Treatment Market Analysis

10.1. Market Value Forecast, By Country

10.1.1.Y-o-Y Growth Projections, By Country

10.1.2.Market Share & Basis Point (BPS) Analysis, By Country

10.1.3.Market Attractiveness Analysis, By Country

10.1.4.Brazil 

10.1.5.Mexico 

10.1.6.Rest of Latin America 

10.2. Market Value Forecast, By Drug Type 

10.2.1.Y-o-Y Growth Projections, By Drug Type

10.2.2.Market Share & Basis Point (BPS) Analysis, By Drug Type

10.2.3.Market Attractiveness Analysis, By Drug Type

10.2.4.Penicillin & Combinations 

10.2.4.1. Amoxicillin

10.2.4.2. Amoxicillin+ Clavulanate Potassium 

10.2.4.3. Others

10.2.5.Quinolones

10.2.5.1. Ciprofloxacin

10.2.5.2. Levofloxacin

10.2.5.3. Nalidixic acid

10.2.5.4. Norfloxacin

10.2.5.5. Others

10.2.6.Cephalosporin

10.2.6.1. Cefuroxime

10.2.6.2. Ceftriaxone

10.2.6.3. Cefixime

10.2.6.4. Cephalexin

10.2.7.Aminoglycoside Antibiotics

10.2.7.1. Amikacin

10.2.7.2. Gentamicin

10.2.8.Sulphonamides

10.2.8.1. Sulfamethoxazole + Trimethoprim

10.2.9.Azoles and Amphotericin B

10.2.10. Tetracycline

10.2.10.1.Doxycycline

10.2.11. Nitrofurans 

10.2.11.1.Nitrofurantoin 

10.2.12. Others

10.3. Market Value Forecast, By Distribution Channel

10.3.1.Y-o-Y Growth Projections, By Distribution Channel

10.3.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel 

10.3.3.Market Attractiveness Analysis, By Distribution Channel

10.3.4.Hospital Pharmacies

10.3.5.Gynecology and Urology Clinics 

10.3.6.Drug Stores

10.3.7.Retail Pharmacies

10.3.8.Online Drug Stores

10.4. Market Value Forecast, By Indication

10.4.1.Y-o-Y Growth Projections, By Indication

10.4.2.Market Share & Basis Point (BPS) Analysis, By Indication

10.4.3.Market Attractiveness Analysis, By Indication

10.4.4.Complicated UTI

10.4.5.Recurring Complicated UTI

10.4.6.Uncomplicated UTI

10.4.7.Neurogenic Bladder Infections

11. Western Europe Urinary Tract Infection Treatment Market Analysis

11.1. Market Value Forecast, By Country

11.1.1.Y-o-Y Growth Projections, By Country

11.1.2.Market Share & Basis Point (BPS) Analysis, By Country

11.1.3.Market Attractiveness Analysis, By Country

11.1.4.UK

11.1.5.Germany

11.1.6.France

11.1.7.Spain

11.1.8.Italy

11.1.9.Nordic

11.1.10. Benelux

11.1.11. Rest of Western Europe

11.2. Market Value Forecast, By Drug Type 

11.2.1.Y-o-Y Growth Projections, By Drug Type

11.2.2.Market Share & Basis Point (BPS) Analysis, By Drug Type

11.2.3.Market Attractiveness Analysis, By Drug Type

11.2.4.Penicillin & Combinations 

11.2.4.1. Amoxicillin

11.2.4.2. Amoxicillin+ Clavulanate Potassium 

11.2.4.3. Others

11.2.5.Quinolones

11.2.5.1. Ciprofloxacin

11.2.5.2. Levofloxacin

11.2.5.3. Nalidixic acid

11.2.5.4. Norfloxacin

11.2.5.5. Others

11.2.6.Cephalosporin

11.2.6.1. Cefuroxime

11.2.6.2. Ceftriaxone

11.2.6.3. Cefixime

11.2.6.4. Cephalexin

11.2.7.Aminoglycoside Antibiotics

11.2.7.1. Amikacin

11.2.7.2. Gentamicin

11.2.8.Sulphonamides

11.2.8.1. Sulfamethoxazole + Trimethoprim

11.2.9.Azoles and Amphotericin B

11.2.10. Tetracycline

11.2.10.1.Doxycycline

11.2.11. Nitrofurans 

11.2.11.1.Nitrofurantoin 

11.2.12. Others

11.3. Market Value Forecast, By Distribution Channel

11.3.1.Y-o-Y Growth Projections, By Distribution Channel

11.3.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel 

11.3.3.Market Attractiveness Analysis, By Distribution Channel

11.3.4.Hospital Pharmacies

11.3.5.Gynecology and Urology Clinics 

11.3.6.Drug Stores

11.3.7.Retail Pharmacies

11.3.8.Online Drug Stores

11.4. Market Value Forecast, By Indication

11.4.1.Y-o-Y Growth Projections, By Indication

11.4.2.Market Share & Basis Point (BPS) Analysis, By Indication

11.4.3.Market Attractiveness Analysis, By Indication

11.4.4.Complicated UTI

11.4.5.Recurring Complicated UTI

11.4.6.Uncomplicated UTI

11.4.7.Neurogenic Bladder Infections

12. Eastern Europe Urinary Tract Infection Treatment Market Analysis

12.1. Market Value Forecast, By Country

12.1.1.Y-o-Y Growth Projections, By Country

12.1.2.Market Share & Basis Point (BPS) Analysis, By Country

12.1.3.Market Attractiveness Analysis, By Country

12.1.4.Russia

12.1.5.Poland

12.1.6.Rest of Eastern Europe

12.2. Market Value Forecast, By Drug Type 

12.2.1.Y-o-Y Growth Projections, By Drug Type

12.2.2.Market Share & Basis Point (BPS) Analysis, By Drug Type

12.2.3.Market Attractiveness Analysis, By Drug Type

12.2.4.Penicillin & Combinations 

12.2.4.1. Amoxicillin

12.2.4.2. Amoxicillin+ Clavulanate Potassium 

12.2.4.3. Others

12.2.5.Quinolones

12.2.5.1. Ciprofloxacin

12.2.5.2. Levofloxacin

12.2.5.3. Nalidixic acid

12.2.5.4. Norfloxacin

12.2.5.5. Others

12.2.6.Cephalosporin

12.2.6.1. Cefuroxime

12.2.6.2. Ceftriaxone

12.2.6.3. Cefixime

12.2.6.4. Cephalexin

12.2.7.Aminoglycoside Antibiotics

12.2.7.1. Amikacin

12.2.7.2. Gentamicin

12.2.8.Sulphonamides

12.2.8.1. Sulfamethoxazole + Trimethoprim

12.2.9.Azoles and Amphotericin B

12.2.10. Tetracycline

12.2.10.1.Doxycycline

12.2.11. Nitrofurans 

12.2.11.1.Nitrofurantoin 

12.2.12. Others

12.3. Market Value Forecast, By Distribution Channel

12.3.1.Y-o-Y Growth Projections, By Distribution Channel

12.3.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel 

12.3.3.Market Attractiveness Analysis, By Distribution Channel

12.3.4.Hospital Pharmacies

12.3.5.Gynecology and Urology Clinics 

12.3.6.Drug Stores

12.3.7.Retail Pharmacies

12.3.8.Online Drug Stores

12.4. Market Value Forecast, By Indication

12.4.1.Y-o-Y Growth Projections, By Indication

12.4.2.Market Share & Basis Point (BPS) Analysis, By Indication

12.4.3.Market Attractiveness Analysis, By Indication

12.4.4.Complicated UTI

12.4.5.Recurring Complicated UTI

12.4.6.Uncomplicated UTI

12.4.7.Neurogenic Bladder Infections

13. APEJ Urinary Tract Infection Treatment Market Analysis

13.1. Market Value Forecast, By Country

13.1.1.Y-o-Y Growth Projections, By Country

13.1.2.Market Share & Basis Point (BPS) Analysis, By Country

13.1.3.Market Attractiveness Analysis, By Country

13.1.4.China

13.1.5.India

13.1.6.ASEAN

13.1.7.Australia & New Zealand

13.1.8.Rest of APEJ

13.2. Market Value Forecast, By Drug Type 

13.2.1.Y-o-Y Growth Projections, By Drug Type

13.2.2.Market Share & Basis Point (BPS) Analysis, By Drug Type

13.2.3.Market Attractiveness Analysis, By Drug Type

13.2.4.Penicillin & Combinations 

13.2.4.1. Amoxicillin

13.2.4.2. Amoxicillin+ Clavulanate Potassium 

13.2.4.3. Others

13.2.5.Quinolones

13.2.5.1. Ciprofloxacin

13.2.5.2. Levofloxacin

13.2.5.3. Nalidixic acid

13.2.5.4. Norfloxacin

13.2.5.5. Others

13.2.6.Cephalosporin

13.2.6.1. Cefuroxime

13.2.6.2. Ceftriaxone

13.2.6.3. Cefixime

13.2.6.4. Cephalexin

13.2.7.Aminoglycoside Antibiotics

13.2.7.1. Amikacin

13.2.7.2. Gentamicin

13.2.8.Sulphonamides

13.2.8.1. Sulfamethoxazole + Trimethoprim

13.2.9.Azoles and Amphotericin B

13.2.10. Tetracycline

13.2.10.1.Doxycycline

13.2.11. Nitrofurans 

13.2.11.1.Nitrofurantoin 

13.2.12. Others

13.3. Market Value Forecast, By Distribution Channel

13.3.1.Y-o-Y Growth Projections, By Distribution Channel

13.3.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel 

13.3.3.Market Attractiveness Analysis, By Distribution Channel

13.3.4.Hospital Pharmacies

13.3.5.Gynecology and Urology Clinics 

13.3.6.Drug Stores

13.3.7.Retail Pharmacies

13.3.8.Online Drug Stores

13.4. Market Value Forecast, By Indication

13.4.1.Y-o-Y Growth Projections, By Indication

13.4.2.Market Share & Basis Point (BPS) Analysis, By Indication

13.4.3.Market Attractiveness Analysis, By Indication

13.4.4.Complicated UTI

13.4.5.Recurring Complicated UTI

13.4.6.Uncomplicated UTI

13.4.7.Neurogenic Bladder Infections

14. Japan Urinary Tract Infection Treatment Market Analysis

14.1. Market Value Forecast, By Drug Type 

14.1.1.Y-o-Y Growth Projections, By Drug Type

14.1.2.Market Share & Basis Point (BPS) Analysis, By Drug Type

14.1.3.Market Attractiveness Analysis, By Drug Type

14.1.4.Penicillin & Combinations 

14.1.4.1. Amoxicillin

14.1.4.2. Amoxicillin+ Clavulanate Potassium 

14.1.4.3. Others

14.1.5.Quinolones

14.1.5.1. Ciprofloxacin

14.1.5.2. Levofloxacin

14.1.5.3. Nalidixic acid

14.1.5.4. Norfloxacin

14.1.5.5. Others

14.1.6.Cephalosporin

14.1.6.1. Cefuroxime

14.1.6.2. Ceftriaxone

14.1.6.3. Cefixime

14.1.6.4. Cephalexin

14.1.7.Aminoglycoside Antibiotics

14.1.7.1. Amikacin

14.1.7.2. Gentamicin

14.1.8.Sulphonamides

14.1.8.1. Sulfamethoxazole + Trimethoprim

14.1.9.Azoles and Amphotericin B

14.1.10. Tetracycline

14.1.10.1.Doxycycline

14.1.11. Nitrofurans 

14.1.11.1.Nitrofurantoin 

14.1.12. Others

14.2. Market Value Forecast, By Distribution Channel

14.2.1.Y-o-Y Growth Projections, By Distribution Channel

14.2.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel 

14.2.3.Market Attractiveness Analysis, By Distribution Channel

14.2.4.Hospital Pharmacies

14.2.5.Gynecology and Urology Clinics 

14.2.6.Drug Stores

14.2.7.Retail Pharmacies

14.2.8.Online Drug Stores

14.3. Market Value Forecast, By Indication

14.3.1.Y-o-Y Growth Projections, By Indication

14.3.2.Market Share & Basis Point (BPS) Analysis, By Indication

14.3.3.Market Attractiveness Analysis, By Indication

14.3.4.Complicated UTI

14.3.5.Recurring Complicated UTI

14.3.6.Uncomplicated UTI

14.3.7.Neurogenic Bladder Infections

15. MEA Urinary Tract Infection Treatment Market Analysis

15.1. Market Value Forecast, By Country

15.1.1.Y-o-Y Growth Projections, By Country

15.1.2.Market Share & Basis Point (BPS) Analysis, By Country

15.1.3.Market Attractiveness Analysis, By Country

15.1.4.GCC Countries

15.1.5.South Africa

15.1.6.North Africa

15.1.7.Rest of MEA

15.2. Market Value Forecast, By Drug Type 

15.2.1.Y-o-Y Growth Projections, By Drug Type

15.2.2.Market Share & Basis Point (BPS) Analysis, By Drug Type

15.2.3.Market Attractiveness Analysis, By Drug Type

15.2.4.Penicillin & Combinations 

15.2.4.1. Amoxicillin

15.2.4.2. Amoxicillin+ Clavulanate Potassium 

15.2.4.3. Others

15.2.5.Quinolones

15.2.5.1. Ciprofloxacin

15.2.5.2. Levofloxacin

15.2.5.3. Nalidixic acid

15.2.5.4. Norfloxacin

15.2.5.5. Others

15.2.6.Cephalosporin

15.2.6.1. Cefuroxime

15.2.6.2. Ceftriaxone

15.2.6.3. Cefixime

15.2.6.4. Cephalexin

15.2.7.Aminoglycoside Antibiotics

15.2.7.1. Amikacin

15.2.7.2. Gentamicin

15.2.8.Sulphonamides

15.2.8.1. Sulfamethoxazole + Trimethoprim

15.2.9.Azoles and Amphotericin B

15.2.10. Tetracycline

15.2.10.1.Doxycycline

15.2.11. Nitrofurans 

15.2.11.1.Nitrofurantoin 

15.2.12. Others

15.3. Market Value Forecast, By Distribution Channel

15.3.1.Y-o-Y Growth Projections, By Distribution Channel

15.3.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel 

15.3.3.Market Attractiveness Analysis, By Distribution Channel

15.3.4.Hospital Pharmacies

15.3.5.Gynecology and Urology Clinics 

15.3.6.Drug Stores

15.3.7.Retail Pharmacies

15.3.8.Online Drug Stores

15.4. Market Value Forecast, By Indication

15.4.1.Y-o-Y Growth Projections, By Indication

15.4.2.Market Share & Basis Point (BPS) Analysis, By Indication

15.4.3.Market Attractiveness Analysis, By Indication

15.4.4.Complicated UTI

15.4.5.Recurring Complicated UTI

15.4.6.Uncomplicated UTI

15.4.7.Neurogenic Bladder Infections

16. Competition Landscape

16.1. Competition Dashboard

16.2. Company Profiles Inclusions

16.2.1.Revenue

16.2.2.Products/Brand Offerings

16.2.3.Key developments

16.2.4.SWOT Analysis

16.3. Company Profiled

16.3.1.Johnson & Johnson Private Ltd.

16.3.2.Boehringer Ingelheim GmbH

16.3.3.Cipla Ltd.

16.3.4.Bayer AG

16.3.5.GlaxoSmithKline Pharmaceuticals Ltd.

16.3.6.Pfizer Inc.

16.3.7.F. Hoffmann–La Roche Ltd.

16.3.8.Novartis AG

16.3.9.AstraZeneca plc

Urinary Tract Infections Market Reports - List of Tables

Table 1: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026

Table 2: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026

Table 3: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2016–2026

Table 4: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Indication, 2016–2026

Table 5: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Region, 2016–2026

Table 6: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast By Country, 2016–2026

Table 7: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026

Table 8: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026

Table 9: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2016–2026

Table 10: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Indication, 2016–2026

Table 11: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast By Country, 2016–2026

Table 12: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026

Table 13: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026

Table 14: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2016–2026

Table 15: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Indication, 2016–2026

Table 16: Western Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast By Country, 2016–2026

Table 17: Western Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026

Table 18: Western Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026

Table 19: Western Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2016–2026

Table 20: Western Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Indication, 2016–2026

Table 21: Eastern Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast By Country, 2016–2026

Table 22: Eastern Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026

Table 23: Eastern Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026

Table 24: Eastern Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2016–2026

Table 25: Eastern Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Indication, 2016–2026

Table 26: APEJ Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast By Country, 2016–2026

Table 27: APEJ Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026

Table 28: APEJ Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026

Table 29: APEJ Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2016–2026

Table 30: APEJ Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Indication, 2016–2026

Table 31: Japan Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026

Table 32: Japan Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026

Table 33: Japan Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2016–2026

Table 34: Japan Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Indication, 2016–2026

Table 35: MEA Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast By Country, 2016–2026

Table 36: MEA Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026

Table 37: MEA Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026

Table 38: MEA Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2016–2026

Table 39: MEA Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Indication, 2016–2026

Urinary Tract Infections Market Reports - List of Figures

 

Figure 1: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast 2016 and 2026

Figure 2: Global Urinary Tract Infection Treatment Market Split By Region (2016)

Figure 3: Global Urinary Tract Infection Treatment Market Split By Drug Type (2016)

Figure 4: Global Urinary Tract Infection Treatment Market Split By Distribution Channel (2016)

Figure 5: Global Urinary Tract Infection Treatment Share Analysis (%) By Drug Type, 2016 & 2026

Figure 6: Global Urinary Tract Infection Treatment Attractiveness Analysis By Drug Type, 2016–2026

Figure 7: Global Urinary Tract Infection Treatment Y-o-Y growth (%) By Drug Type, 2016–2026

Figure 8: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Penicillin & Combinations Segment, 2016–2026

Figure 9: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Quinolones Segment, 2016–2026

Figure 10: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Cephalosporin Segment, 2016–2026

Figure 11: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Aminoglycoside Antibiotics Segment, 2016–2026

Figure 12: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Sulphonamides Segment, 2016–2026

Figure 13: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Azoles and Amphotericin B Segment, 2016–2026

Figure 14: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Tetracycline Segment, 2016–2026

Figure 15: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Nitrofurans Segment, 2016–2026

Figure 16: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Other Drug Type Segment, 2016–2026

Figure 17: Global Urinary Tract Infection Treatment Share Analysis (%) By Distribution Channel, 2016 & 2026

Figure 18: Global Urinary Tract Infection Treatment Attractiveness Analysis By Distribution Channel, 2016–2026

Figure 19: Global Urinary Tract Infection Treatment Y-o-Y growth (%) By Distribution Channel, 2016–2026

Figure 20: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Hospital Pharmacies Segment, 2016–2026

Figure 21: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Gynecology and Urology Clinics Segment, 2016–2026

Figure 22: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Drug Stores Segment, 2016–2026

Figure 23: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Retail Pharmacies Segment, 2016–2026

Figure 24: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Online Drug Stores Segment, 2016–2026

Figure 25: Global Urinary Tract Infection Treatment Share Analysis (%) By Indication, 2016 & 2026

Figure 26: Global Urinary Tract Infection Treatment Attractiveness Analysis By Indication, 2016–2026

Figure 27: Global Urinary Tract Infection Treatment Y-o-Y growth (%) By Indication, 2016–2026

Figure 28: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Complicated UTI Segment, 2016–2026

Figure 29: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Recurring Complicated UTI Segment, 2016–2026

Figure 30: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Uncomplicated UTI Segment, 2016–2026

Figure 31: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Neurogenic Bladder Infections Segment, 2016–2026

Figure 32: Global Urinary Tract Infection Treatment Share Analysis (%) By Region, 2016 & 2026

Figure 33: Global Urinary Tract Infection Treatment Attractiveness Analysis By Region, 2016–2026

Figure 34: Global Urinary Tract Infection Treatment Y-o-Y growth (%) By Region, 2016–2026

Figure 35: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By North America, 2016–2026

Figure 36: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Latin America, 2016–2026

Figure 37: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Western Europe, 2016–2026

Figure 38: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Eastern Europe, 2016–2026

Figure 39: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By APEJ, 2016–2026

Figure 40: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Japan, 2016–2026

Figure 41: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By MEA, 2016–2026

Figure 42: North America Urinary Tract Infection Treatment Share Analysis (%) By Country, 2016 & 2026

Figure 43: North America Urinary Tract Infection Treatment Attractiveness Analysis By Country, 2016–2026

Figure 44: North America Urinary Tract Infection Treatment Y-o-Y growth (%) By Country, 2016–2026

Figure 45: North America Urinary Tract Infection Treatment Share Analysis (%) By Drug Type, 2016 & 2026

Figure 46: North America Urinary Tract Infection Treatment Attractiveness Analysis By Drug Type, 2016–2026

Figure 47: North America Urinary Tract Infection Treatment Y-o-Y growth (%) By Drug Type, 2016–2026

Figure 48: North America Urinary Tract Infection Treatment Share Analysis (%) By Distribution Channel, 2016 & 2026

Figure 49: North America Urinary Tract Infection Treatment Attractiveness Analysis By Distribution Channel, 2016–2026

Figure 50: North America Urinary Tract Infection Treatment Y-o-Y growth (%) By Distribution Channel, 2016–2026

Figure 51: North America Urinary Tract Infection Treatment Share Analysis (%) By Indication, 2016 & 2026

Figure 52: North America Urinary Tract Infection Treatment Attractiveness Analysis By Indication, 2016–2026

Figure 53: North America Urinary Tract Infection Treatment Y-o-Y growth (%) By Indication, 2016–2026

Figure 54: Latin America Urinary Tract Infection Treatment Share Analysis (%) By Country, 2016 & 2026

Figure 55: Latin America Urinary Tract Infection Treatment Attractiveness Analysis By Country, 2016–2026

Figure 56: Latin America Urinary Tract Infection Treatment Y-o-Y growth (%) By Country, 2016–2026

Figure 57: Latin America Urinary Tract Infection Treatment Share Analysis (%) By Drug Type, 2016 & 2026

Figure 58: Latin America Urinary Tract Infection Treatment Attractiveness Analysis By Drug Type, 2016–2026

Figure 59: Latin America Urinary Tract Infection Treatment Y-o-Y growth (%) By Drug Type, 2016–2026

Figure 60: Latin America Urinary Tract Infection Treatment Share Analysis (%) By Distribution Channel, 2016 & 2026

Figure 61: Latin America Urinary Tract Infection Treatment Attractiveness Analysis By Distribution Channel, 2016–2026

Figure 62: Latin America Urinary Tract Infection Treatment Y-o-Y growth (%) By Distribution Channel, 2016–2026

Figure 63: Latin America Urinary Tract Infection Treatment Share Analysis (%) By Indication, 2016 & 2026

Figure 64: Latin America Urinary Tract Infection Treatment Attractiveness Analysis By Indication, 2016–2026

Figure 65: Latin America Urinary Tract Infection Treatment Y-o-Y growth (%) By Indication, 2016–2026

Figure 66: Western Europe Urinary Tract Infection Treatment Share Analysis (%) By Country, 2016 & 2026

Figure 67: Western Europe Urinary Tract Infection Treatment Attractiveness Analysis By Country, 2016–2026

Figure 68: Western Europe Urinary Tract Infection Treatment Y-o-Y growth (%) By Country, 2016–2026

Figure 69: Western Europe Urinary Tract Infection Treatment Share Analysis (%) By Drug Type, 2016 & 2026

Figure 70: Western Europe Urinary Tract Infection Treatment Attractiveness Analysis By Drug Type, 2016–2026

Figure 71: Western Europe Urinary Tract Infection Treatment Y-o-Y growth (%) By Drug Type, 2016–2026

Figure 72: Western Europe Urinary Tract Infection Treatment Share Analysis (%) By Distribution Channel, 2016 & 2026

Figure 73: Western Europe Urinary Tract Infection Treatment Attractiveness Analysis By Distribution Channel, 2016–2026

Figure 74: Western Europe Urinary Tract Infection Treatment Y-o-Y growth (%) By Distribution Channel, 2016–2026

Figure 75: Western Europe Urinary Tract Infection Treatment Share Analysis (%) By Indication, 2016 & 2026

Figure 76: Western Europe Urinary Tract Infection Treatment Attractiveness Analysis By Indication, 2016–2026

Figure 77: Western Europe Urinary Tract Infection Treatment Y-o-Y growth (%) By Indication, 2016–2026

Figure 78: Eastern Europe Urinary Tract Infection Treatment Share Analysis (%) By Country, 2016 & 2026

Figure 79: Eastern Europe Urinary Tract Infection Treatment Attractiveness Analysis By Country, 2016–2026

Figure 80: Eastern Europe Urinary Tract Infection Treatment Y-o-Y growth (%) By Country, 2016–2026

Figure 81: Eastern Europe Urinary Tract Infection Treatment Share Analysis (%) By Drug Type, 2016 & 2026

Figure 82: Eastern Europe Urinary Tract Infection Treatment Attractiveness Analysis By Drug Type, 2016–2026

Figure 83: Eastern Europe Urinary Tract Infection Treatment Y-o-Y growth (%) By Drug Type, 2016–2026

Figure 84: Eastern Europe Urinary Tract Infection Treatment Share Analysis (%) By Distribution Channel, 2016 & 2026

Figure 85: Eastern Europe Urinary Tract Infection Treatment Attractiveness Analysis By Distribution Channel, 2016–2026

Figure 86: Eastern Europe Urinary Tract Infection Treatment Y-o-Y growth (%) By Distribution Channel, 2016–2026

Figure 87: Eastern Europe Urinary Tract Infection Treatment Share Analysis (%) By Indication, 2016 & 2026

Figure 88: Eastern Europe Urinary Tract Infection Treatment Attractiveness Analysis By Indication, 2016–2026

Figure 89: Eastern Europe Urinary Tract Infection Treatment Y-o-Y growth (%) By Indication, 2016–2026

Figure 90: APEJ Urinary Tract Infection Treatment Share Analysis (%) By Country, 2016 & 2026

Figure 91: APEJ Urinary Tract Infection Treatment Attractiveness Analysis By Country, 2016–2026

Figure 92: APEJ Urinary Tract Infection Treatment Y-o-Y growth (%) By Country, 2016–2026

Figure 93: APEJ Urinary Tract Infection Treatment Share Analysis (%) By Drug Type, 2016 & 2026

Figure 94: APEJ Urinary Tract Infection Treatment Attractiveness Analysis By Drug Type, 2016–2026

Figure 95: APEJ Urinary Tract Infection Treatment Y-o-Y growth (%) By Drug Type, 2016–2026

Figure 96: APEJ Urinary Tract Infection Treatment Share Analysis (%) By Distribution Channel, 2016 & 2026

Figure 97: APEJ Urinary Tract Infection Treatment Attractiveness Analysis By Distribution Channel, 2016–2026

Figure 98: APEJ Urinary Tract Infection Treatment Y-o-Y growth (%) By Distribution Channel, 2016–2026

Figure 99: APEJ Urinary Tract Infection Treatment Share Analysis (%) By Indication, 2016 & 2026

Figure 100: APEJ Urinary Tract Infection Treatment Attractiveness Analysis By Indication, 2016–2026

Figure 101: APEJ Urinary Tract Infection Treatment Y-o-Y growth (%) By Indication, 2016–2026

Figure 102: Japan Urinary Tract Infection Treatment Share Analysis (%) By Drug Type, 2016 & 2026

Figure 103: Japan Urinary Tract Infection  Treatment Attractiveness Analysis By Drug Type, 2016–2026

Figure 104: Japan Urinary Tract Infection Treatment Y-o-Y growth (%) By Drug Type, 2016–2026

Figure 105: Japan Urinary Tract Infection Treatment Share Analysis (%) By Distribution Channel, 2016 & 2026

Figure 106: Japan Urinary Tract Infection Treatment Attractiveness Analysis By Distribution Channel, 2016–2026

Figure 107: Japan Urinary Tract Infection Treatment Y-o-Y growth (%) By Distribution Channel, 2016–2026

Figure 108: Japan Urinary Tract Infection Treatment Share Analysis (%) By Indication, 2016 & 2026

Figure 109: Japan Urinary Tract Infection Treatment Attractiveness Analysis By Indication, 2016–2026

Figure 110: Japan Urinary Tract Infection Treatment Y-o-Y growth (%) By Indication, 2016–2026

Figure 111: MEA Urinary Tract Infection Treatment Share Analysis (%) By Country, 2016 & 2026

Figure 112: MEA Urinary Tract Infection Treatment Attractiveness Analysis By Country, 2016–2026

Figure 113: MEA Urinary Tract Infection Treatment Y-o-Y growth (%) By Country, 2016–2026

Figure 114: MEA Urinary Tract Infection Treatment Share Analysis (%) By Drug Type, 2016 & 2026

Figure 115: MEA Urinary Tract Infection Treatment Attractiveness Analysis By Drug Type, 2016–2026

Figure 116: MEA Urinary Tract Infection Treatment Y-o-Y growth (%) By Drug Type, 2016–2026

Figure 117: MEA Urinary Tract Infection Treatment Share Analysis (%) By Distribution Channel, 2016 & 2026

Figure 118: MEA Urinary Tract Infection Treatment Attractiveness Analysis By Distribution Channel, 2016–2026

Figure 119: MEA Urinary Tract Infection Treatment Y-o-Y growth (%) By Distribution Channel, 2016–2026

Figure 120: MEA Urinary Tract Infection Treatment Share Analysis (%) By Indication, 2016 & 2026

Figure 121: MEA Urinary Tract Infection Treatment Attractiveness Analysis By Indication, 2016–2026

Figure 122: MEA Urinary Tract Infection Treatment Y-o-Y growth (%) By Indication, 2016–2026